Paediatric Neurology and Therapeutic Carbohydrate Restriction

Key Takeaways

• Ketogenic diet shows promise for neonatal hypoxic‑ischemic encephalopathy
• Preterm NICU case reduced lactate and stabilized metabolism with keto therapy
• Modified Atkins diet improved behavior and EEG in PTEN‑related autism
• Well‑formulated keto diets can meet pediatric nutritional needs without deficits
• Researchers urge larger trials to confirm safety and efficacy in children

Pulse Analysis

Since the 1920s the ketogenic diet has been a mainstay for drug‑resistant epilepsy, leveraging a metabolic shift from glucose to ketone bodies to modulate inflammation, oxidative stress and epigenetic signaling. Recent preclinical work extends these mechanisms to neonatal hypoxic‑ischemic encephalopathy (HIE), where ketone‑driven ATP production and reduced glutamate excitotoxicity could protect the injured brain. A 2026 scoping review concluded that, while human data are sparse, the safety profile observed in neonatal epilepsy suggests feasibility for HIE trials, prompting calls for systematic investigation.

Early clinical anecdotes reinforce the theoretical promise. D’Amato et al. reported a preterm infant with mitochondrial DNA depletion syndrome who, after a gradual 1:1 ketogenic regimen delivered intravenously and via nasogastric tube, showed rapid lactate clearance, cessation of bicarbonate support and stable growth. In a separate case, a 7‑year‑old with a PTEN mutation‑associated autism spectrum disorder achieved therapeutic ketosis on a modified Atkins protocol, leading to measurable improvements in emotional regulation, motor skills, EEG patterns and inflammatory markers within two weeks. A 2025 nutrient analysis of pediatric epilepsy patients demonstrated that a well‑designed modified Atkins diet can increase fiber, omega‑3 fatty acids and essential micronutrients while maintaining therapeutic ketone levels, dispelling concerns about long‑term deficiencies.

For clinicians, these findings suggest that therapeutic carbohydrate restriction could become a versatile adjunct across a spectrum of pediatric neuro‑developmental disorders, provided that rigorous metabolic monitoring and individualized nutrient supplementation are in place. Importantly, the ketogenic approach for neurological indications differs from the broader low‑carbohydrate strategies used for obesity or type 2 diabetes, emphasizing strict macronutrient ratios and seizure‑focused outcomes. The field now faces a pivotal research agenda: randomized controlled trials to define optimal ratios, duration, and safety thresholds, as well as health‑economic analyses to assess cost‑effectiveness in intensive care settings. Successful validation could reshape standard care pathways for neonatal brain injury, refractory epilepsy and autism, offering a non‑pharmacologic option with durable neuroprotective benefits.